Bristol Myers Squibb (BMY) +2.3% premarket after results from an early-stage study show its...

|By:, SA News Editor

Bristol Myers Squibb (BMY) +2.3% premarket after results from an early-stage study show its BMS-936658 experimental drug that helps the immune system attack cancer cells can reduce the size of tumors in patients with melanoma and non-small cell lung cancers. (also)